Published in J Biol Chem on April 04, 2006
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem (2010) 1.48
Krüppel-like factors in cancer. Nat Rev Cancer (2013) 1.32
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer (2007) 1.09
KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem (2009) 1.08
Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res (2009) 1.07
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer (2009) 1.01
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01
Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Krüppel-like factor 5. J Biol Chem (2013) 0.97
Krüppel-like factors: three fingers in control. Hum Genomics (2010) 0.95
Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res (2011) 0.95
Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. Am J Pathol (2010) 0.93
A comprehensive and high-resolution genome-wide response of p53 to stress. Cell Rep (2014) 0.92
Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays. Cancer Cell Int (2012) 0.90
Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res (2011) 0.90
Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int J Cancer (2014) 0.87
Kruppel-like factor 5 transcription factor promotes microsomal prostaglandin E2 synthase 1 gene transcription in breast cancer. J Biol Chem (2013) 0.84
Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression. Breast Cancer Res (2011) 0.83
Different expression patterns and functions of acetylated and unacetylated Klf5 in the proliferation and differentiation of prostatic epithelial cells. PLoS One (2013) 0.80
KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. Oncogene (2015) 0.80
Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5. Oncotarget (2015) 0.79
T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin. Mol Cancer Ther (2016) 0.78
Krüpple-like factor 5 is required for proper maintenance of adult intestinal crypt cellular proliferation. Dig Dis Sci (2014) 0.78
1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int J Oncol (2009) 0.77
Increased pulmonary vascular expression of Krüppel-like factor 5 and activated survivin in experimental congenital diaphragmatic hernia. Pediatr Surg Int (2014) 0.76
The twisted survivin connection to angiogenesis. Mol Cancer (2015) 0.76
Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors. BMC Cancer (2015) 0.76
Yin Yang 1 regulates the transcriptional repression of Survivin. Biochem Biophys Res Commun (2014) 0.76
Expression of Krűppel-like factor 5 in gastric cancer and its clinical correlation in Taiwan. Virchows Arch (2011) 0.76
Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector. PLoS One (2013) 0.75
MicroRNA-153 inhibits the proliferation and invasion of human laryngeal squamous cell carcinoma by targeting KLF5. Exp Ther Med (2016) 0.75
Serum Survivin and TP53 Gene Expression in Children with Acute Lymphoblastic Leukemia. Iran J Public Health (2012) 0.75
Klf5 regulates muscle differentiation by directly targeting muscle-specific genes in cooperation with MyoD in mice. Elife (2016) 0.75
Krüppel-Like Factor 5 Promotes Epithelial Proliferation and DNA Damage Repair in the Intestine of Irradiated Mice. Int J Biol Sci (2015) 0.75
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol (2009) 3.21
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci (2009) 1.82
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene (2005) 1.64
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet (2008) 1.62
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell (2009) 1.60
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58
Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem (2005) 1.56
A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene (2002) 1.55
The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res (2010) 1.50
Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50
Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res (2005) 1.49
KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate (2003) 1.47
KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer (2006) 1.44
The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem (2008) 1.39
Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells. Genes Cancer (2011) 1.32
Contribution of Vh gene replacement to the primary B cell repertoire. Immunity (2003) 1.32
Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) (2006) 1.32
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res (2003) 1.29
Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clin Cancer Res (2007) 1.29
EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci U S A (2008) 1.28
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer (2007) 1.26
DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther (2002) 1.26
Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials (2010) 1.25
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol (2010) 1.22
Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem (2008) 1.21
Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer (2008) 1.20
Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res (2010) 1.18
Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis (2003) 1.17
PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res (2004) 1.15
TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis (2011) 1.15
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials (2011) 1.14
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol (2006) 1.14
Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res (2008) 1.13
YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am J Pathol (2012) 1.12
Reactive oxygen species control senescence-associated matrix metalloproteinase-1 through c-Jun-N-terminal kinase. J Cell Physiol (2010) 1.12
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol (2005) 1.10
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res (2010) 1.10
KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem (2009) 1.08
Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood (2009) 1.08
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res (2010) 1.07
Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol (2011) 1.07
Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem Biol Drug Des (2009) 1.05
The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol (2009) 1.04
Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol (2006) 1.03
T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging (2011) 1.03
Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells. J Biol Chem (2009) 1.03
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer (2009) 1.03
Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle (2011) 1.02
An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene (2004) 1.02
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One (2010) 1.01
Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer (2011) 1.01
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J Pathol (2009) 1.00
Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem (2004) 1.00
Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat (2008) 1.00
Opposing effects of KLF5 on the transcription of MYC in epithelial proliferation in the context of transforming growth factor beta. J Biol Chem (2009) 0.99
Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene (2003) 0.99
The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Mol Endocrinol (2011) 0.99
Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate (2006) 0.98
MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol (2011) 0.98
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther (2008) 0.97
The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation. Arterioscler Thromb Vasc Biol (2012) 0.97
Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem (2008) 0.96
WWP1: a versatile ubiquitin E3 ligase in signaling and diseases. Cell Mol Life Sci (2011) 0.96
Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther (2011) 0.95
KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. Mol Cell Biol (2013) 0.94
Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. Biochem J (2011) 0.94
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res (2012) 0.94